INSTRUCTIONS Rheumatoid arthritis: New treatments, better outcomes
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 23. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $24.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is November 30, 2014.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.5 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.5 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454.
Your certificate is valid in all states. This activity has been assigned 2.5 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Rheumatoid arthritis: New treatments, better outcomes
General Purpose: The purpose of this learning activity is to provide information about advances in treating RA. Learning Objectives: After reading this article and taking the test, the learner will be able to: 1. Identify current practice recommendations for treating RA. 2. Discuss new drug therapies for RA.
1. In comparison to previous criteria, the 2010 RA classification criteria
a. reduced sensitivity but improved specificity.
b. improved sensitivity but reduced specificity.
c. improved both sensitivity and specificity.
d. reduced both sensitivity and specificity.
2. For clinical trials, the Boolean-based definition of RA remission includes a C-reactive protein level of
a. ≤ 1.0 mg/dL.
b. ≤ 1.8 mg/dL.
c. ≤ 2.2 mg/dL.
d. ≤ 3.3 mg/dL.
3. Guidelines recommend that to prevent joint damage, appropriate drug therapy should begin within how long after diagnosis?
a. 1 week
b. 1 month
c. 3 months
d. 1 year
4. Using the treat-to-target criteria, how often should medications be adjusted until the target is met?
a. each week
b. each month
c. every 2 months
d. at least every 3 months
5. All of the following indicate potential for a poor prognosis except
a. erosions on radiography.
b. functional limitations.
c. extra-articular disease.
d. need for DMARD therapy.
6. What is the first line of therapy for moderate-to-severe RA?
7. According to Finckh and colleagues, evidence for the cost-effectiveness of using biologic agents as an early therapy is
c. highly significant.
8. Which FDA-approved drug do the authors not recommend due to limited effectiveness?
9. Which of the following drugs is an anti-TNF alpha agent?
10. Radstake and colleagues found that some patients who take anti-TNF alpha agents
a. develop serum antibodies to the drug.
b. are at risk for tumor lysis syndrome.
c. are at risk for cardiovascular disease.
d. develop hypercholesterolemia.
11. Which anti-TNF alpha agent has the longest half-life?
b. certolizumab pegol
12. Tocilizumab is an example of a(an)
a. anti-TNF alpha agent.
b. Beta-cell inhibitor.
c. IL-6 receptor inhibitor.
d. IL-6 agonist.
13. Which drug is a beta-cell inhibitor that has FDA approval for patients who fail to respond well to anti-TNF alpha agents?
b. certolizumab pegol
14. Taking certolizumab pegol or golimumab presents a risk of reactivating TB and
a. hepatitis B.
b. hepatitis C.
c. herpes zoster.
d. pulmonary fibrosis.
15. Which of the following is contraindicated during tocilizumab therapy?
a. tuberculin skin testing
b. co-therapy with methotrexate
c. live or attenuated vaccinations
d. treatment with antibiotics
16. The ACR indicates that patients with RA and hepatitis C can be treated with
17. Before beginning therapy with biologic agents, the ACR recommends screening all patients for
a. latent TB.
b. hepatitis B antibodies.
c. hepatitis C infection.
d. demyelinating diseases.
18. Which score on the ACR/EULAR criteria for RA indicates an RA diagnosis?
a. < 6
b. ≥ 6
c. ≥ 12